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With the availability of increased information about the 
role of common genetic polymorphisms in disease sus-
cep  tibility, response to therapy and toxicity of therapies, 
the prospect of increasingly personalized medicine is 
becoming a reality. Palomino-Morales and colleagues [1] 
report the novel observation that a common poly-
morphism in the gene for methylene tetrahydrofolate 
reductase (MTHFR) that markedly reduces enzyme 
activity (by as much as 65% in homozygotes) may 
predispose to the development of atherosclerotic cardio-
vascular disease (ASCVD) in patients with rheumatoid 
arthritis (RA).
Although RA primarily aﬀ  ects the joints, it is a systemic 
disease that clearly contributes to a marked increase in 
the risk for development of ASCVD (for example, [2]). 
Th  e increased risk of developing ASCVD has been 
attributed to generalized inﬂ   ammation that enhances 
development of atherosclerosis, the use of steroids, 
changes in lipid proﬁ  les and other unknown mechanisms.
Elevated homocysteine levels have long been associated 
with ASCVD (for example, [3]) and homo  cysteine is a 
direct toxin for the vascular endo  thelium. Low dose 
methotrexate therapy, by inhibiting MTHFR, diminishes 
recycling of homocysteine to methio  nine, leading to 
increases in plasma homocysteine, although folic acid 
supplementation abrogates the increase in homocysteine 
levels in methotrexate-treated patients with RA [4]. One 
potential contributor to homo  cysteine elevation is 
genetic alterations in MTHFR; two common poly  mor-
phisms in this enzyme have previously been reported to 
alter MTHFR activity (C677T and A1298C).
Th  e A1298C polymorphism is quite common and is 
present in as many normal individuals (40% were AC 
heterozygotes and 10% were homozygous CC) as RA 
patients (41% were heterozygotes and 10% were homo  zy-
gous for the C allele). Th   e striking ﬁ  nding by Palomino-
Morales and colleagues was that RA patients with 
cardiovascular events were more likely to have the C 
allele of A1298C than those without (62% versus 50%, 
respectively) and the accumulated risk increased over 
time was strongly associated with the C allele of the 
A1298C polymorphism. It is interesting to note that the 
polymorphism associated with more marked declines in 
MTHFR activity, the C677T polymorphism, was not 
associated with a greater risk for cardiovascular disease. 
Th  e numbers were probably too small to determine 
whether there was an interaction between these two 
common polymorphisms that further contributed to risk.
In some of the patients with RA the authors were able 
to directly probe the health of the endothelium by 
measuring the ﬂ   ow-dependent forearm vasodilatation 
and found that the RA patients with the minority A1298C 
allele in MTHFR had diminished vasodilatory responses, 
consistent with a less healthy vascular endothelium.
Patients with the C677T polymorphism, but not the 
A1298C polymorphism, are at greater risk for developing 
complications of methotrexate therapy and methotrexate 
therapy may ameliorate the risk of ASCVD in patients 
with RA [5,6]. Th   us, it would be interesting to determine 
whether methotrexate therapy aﬀ  ected the frequency of 
cardiovascular events in this population and whether 
there was any interaction between methotrexate and 
genetic risk for cardiovascular disease in this population. 
Moreover, it would be important to know how many of 
these patients were taking folic acid supplements since 
folic acid supplementation has previously been shown to 
lower homocysteine levels in patients taking metho-
trexate [4,7-9], presumably by providing higher levels of 
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© 2010 BioMed Central Ltdsubstrate for the enzyme, and it is possible that folic acid 
supplementation in this group might have had a greater 
eﬀ  ect in the patients with the polymorphism on reducing 
risk of cardiovascular events.
More often than not, candidate genetic association 
studies, such as that described here, are not reproducible 
[10] and it is possible that this study may share the fate 
common to so many of these types of candidate gene 
studies. Nonetheless, Palmino-Morales and colleagues 
have made an interesting observation that may suggest a 
contributing factor to the development of cardiovascular 
disease in patients with RA. Moreover, this study 
provides an even greater rationale for the addition of folic 
acid to the therapy for RA, prevention of cardiovascular 
disease.
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